190 related articles for article (PubMed ID: 16159618)
1. Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma.
Wen MC; Wei CH; Hu ZQ; Srivastava K; Ko J; Xi ST; Mu DZ; Du JB; Li GH; Wallenstein S; Sampson H; Kattan M; Li XM
J Allergy Clin Immunol; 2005 Sep; 116(3):517-24. PubMed ID: 16159618
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of an antiasthma herbal Formula (ASHMI) in adult subjects with asthma: a randomized, double-blinded, placebo-controlled, dose-escalation phase I study.
Kelly-Pieper K; Patil SP; Busse P; Yang N; Sampson H; Li XM; Wisnivesky JP; Kattan M
J Altern Complement Med; 2009 Jul; 15(7):735-43. PubMed ID: 19586409
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and immunological actions of a herbal medicine ASHMI on allergic asthma.
Zhang T; Srivastava K; Wen MC; Yang N; Cao J; Busse P; Birmingham N; Goldfarb J; Li XM
Phytother Res; 2010 Jul; 24(7):1047-55. PubMed ID: 19998324
[TBL] [Abstract][Full Text] [Related]
4. The traditional Chinese herbal formula ASHMI inhibits allergic lung inflammation in antigen-sensitized and antigen-challenged aged mice.
Busse PJ; Schofield B; Birmingham N; Yang N; Wen MC; Zhang T; Srivastava K; Li XM
Ann Allergy Asthma Immunol; 2010 Mar; 104(3):236-46. PubMed ID: 20377113
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of modified Mai-Men-Dong-Tang for treatment of allergic asthma.
Hsu CH; Lu CM; Chang TT
Pediatr Allergy Immunol; 2005 Feb; 16(1):76-81. PubMed ID: 15693916
[TBL] [Abstract][Full Text] [Related]
6. Chinese herbal medicine formula for acute asthma: A multi-center, randomized, double-blind, proof-of-concept trial.
Zhang HP; Wang L; Wang Z; Xu XR; Zhou XM; Liu G; He LY; Wang J; Hsu A; Li WM; Wang G
Respir Med; 2018 Jul; 140():42-49. PubMed ID: 29957279
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of the Chinese herbal medicine formula STA-1 in the treatment of allergic asthma.
Chang TT; Huang CC; Hsu CH
Phytother Res; 2006 May; 20(5):342-7. PubMed ID: 16619360
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma.
Chapman KR; Patel P; D'Urzo AD; Alexander M; Mehra S; Oedekoven C; Engelstätter R; Boulet LP
Allergy; 2005 Mar; 60(3):330-7. PubMed ID: 15679718
[TBL] [Abstract][Full Text] [Related]
10. The anti-asthma herbal medicine ASHMI acutely inhibits airway smooth muscle contraction via prostaglandin E2 activation of EP2/EP4 receptors.
Srivastava K; Sampson HA; Emala CW; Li XM
Am J Physiol Lung Cell Mol Physiol; 2013 Dec; 305(12):L1002-10. PubMed ID: 24163140
[TBL] [Abstract][Full Text] [Related]
11. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.
Galant SP; van Bavel J; Finn A; Gross G; Pleskow W; Brown A; Hamedani AG; Harding SM
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):273-80. PubMed ID: 10094218
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of ciclesonide 160 and 640 microg/day in severe asthma.
Bateman ED; Cheung D; Lapa e Silva J; Göhring UM; Schäfer M; Engelstätter R
Pulm Pharmacol Ther; 2008; 21(3):489-98. PubMed ID: 18178494
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations.
Belda J; Margarit G; Martínez C; Bellido-Casado J; Casan P; Torrejón M; Brufal M; Rodríguez-Jerez F; Sanchis J
Eur Respir J; 2007 Dec; 30(6):1143-9. PubMed ID: 17690122
[TBL] [Abstract][Full Text] [Related]
14. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
Milgrom H; Fick RB; Su JQ; Reimann JD; Bush RK; Watrous ML; Metzger WJ
N Engl J Med; 1999 Dec; 341(26):1966-73. PubMed ID: 10607813
[TBL] [Abstract][Full Text] [Related]
15. Constituents of the anti-asthma herbal formula ASHMI(TM) synergistically inhibit IL-4 and IL-5 secretion by murine Th2 memory cells, and eotaxin by human lung fibroblasts in vitro.
Jayaprakasam B; Yang N; Wen MC; Wang R; Goldfarb J; Sampson H; Li XM
J Integr Med; 2013 May; 11(3):195-205. PubMed ID: 23743163
[TBL] [Abstract][Full Text] [Related]
16. [The long term effect of small dose budesonide turbuhaler on mild bronchial asthma].
Weng JL; Zheng YS; Ma QF
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):88-92. PubMed ID: 15854388
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
18. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
[TBL] [Abstract][Full Text] [Related]
19. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
[TBL] [Abstract][Full Text] [Related]
20. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.
Beeh KM; Kanniess F; Wagner F; Schilder C; Naudts I; Hammann-Haenni A; Willers J; Stocker H; Mueller P; Bachmann MF; Renner WA
J Allergy Clin Immunol; 2013 Mar; 131(3):866-74. PubMed ID: 23384679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
